Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Helix Biopharma Corp. (HBPCF) had Return on Tangible Equity of 7236.81% for the most recently reported fiscal quarter, ending 2025-01-31.
| Income Statement Financials | |
-- |
|
$-0.97M |
|
-- |
|
-- |
|
$0.90M |
|
$-0.90M |
|
$-0.07M |
|
$-0.97M |
|
$-0.97M |
|
$-0.97M |
|
$-0.97M |
|
$-0.97M |
|
$-0.97M |
|
$-0.90M |
|
$-0.90M |
|
50.06M |
|
50.06M |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$1.57M |
|
$0.01M |
|
$0.01M |
|
$1.58M |
|
$1.59M |
|
-- |
|
-- |
|
$1.59M |
|
$-0.01M |
|
$-0.01M |
|
$-0.01M |
|
53.02M |
|
| Cash Flow Statement Financials | |
$-1.27M |
|
$0.01M |
|
$1.90M |
|
$0.76M |
|
$1.40M |
|
$0.64M |
|
$0.07M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.99 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.25M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
7239.33% |
|
|
Return on Tangible Equity |
7236.81% |
-61.33% |
|
7236.84% |
|
$-0.00 |
|
$-0.03 |
|
$-0.03 |
|